Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK5864399
- Development stage
- Unknown
- Lead developer
- GSK
01
Overview
GSK5864399 is an early-stage investigational oncology drug being developed by GSK. It is currently being evaluated in a Phase 1/2 first-in-human clinical trial (jRCT2031260632) sponsored by GlaxoSmithKline K.K. in Japan. The study is an open-label, multicenter, dose-escalation and dose-expansion trial designed to assess the safety, tolerability, and preliminary efficacy of GSK5864399 in adult patients with selected advanced unresectable metastatic solid tumors, specifically colorectal cancer and non-small cell lung cancer that have progressed after prior systemic therapy. Detailed pharmacological properties, including its molecular target and modality, have not been publicly disclosed.
Beyond the preview
Go deeper on GSK5864399.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK5864399.